Alimera Sciences (NASDAQ:ALIM) Research Coverage Started at StockNews.com

Research analysts at StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a report issued on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on ALIM. Alliance Global Partners restated a “neutral” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, HC Wainwright lowered Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price on the stock. in a research report on Tuesday, June 25th.

Alimera Sciences Stock Performance

NASDAQ:ALIM opened at $5.54 on Friday. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.79 and a quick ratio of 2.62. Alimera Sciences has a 1 year low of $2.61 and a 1 year high of $5.65. The stock’s 50 day simple moving average is $5.56 and its two-hundred day simple moving average is $4.43. The company has a market cap of $290.24 million, a price-to-earnings ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. As a group, equities analysts anticipate that Alimera Sciences will post -0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Glazer Capital LLC purchased a new stake in shares of Alimera Sciences during the second quarter worth $3,067,000. Ancora Advisors LLC purchased a new position in Alimera Sciences in the first quarter worth approximately $915,000. Renaissance Technologies LLC grew its position in shares of Alimera Sciences by 3.9% in the 2nd quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock valued at $1,010,000 after buying an additional 6,900 shares during the last quarter. Finally, Deltec Asset Management LLC purchased a new position in shares of Alimera Sciences during the second quarter worth approximately $690,000. 99.83% of the stock is owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).